Hyperion Capital Advisors LP Has $18.08 Million Position in Elevance Health, Inc. (NYSE:ELV)

Hyperion Capital Advisors LP boosted its holdings in Elevance Health, Inc. (NYSE:ELV) by 26.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 48,998 shares of the company’s stock after buying an additional 10,105 shares during the quarter. Elevance Health accounts for about 9.3% of Hyperion Capital Advisors LP’s investment portfolio, making the stock its 3rd largest position. Hyperion Capital Advisors LP’s holdings in Elevance Health were worth $18,075,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the stock. Accredited Wealth Management LLC acquired a new stake in shares of Elevance Health during the fourth quarter valued at approximately $25,000. Flagship Wealth Advisors LLC purchased a new stake in shares of Elevance Health in the fourth quarter valued at $26,000. WealthTrak Capital Management LLC purchased a new stake in shares of Elevance Health in the fourth quarter valued at $29,000. Lee Danner & Bass Inc. acquired a new stake in shares of Elevance Health in the fourth quarter worth $30,000. Finally, OFI Invest Asset Management acquired a new position in Elevance Health during the fourth quarter valued at $29,000. Institutional investors own 89.24% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Mizuho lifted their target price on Elevance Health from $455.00 to $505.00 and gave the company an “outperform” rating in a research note on Wednesday, April 9th. Wells Fargo & Company lowered their price objective on shares of Elevance Health from $483.00 to $478.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. Barclays increased their target price on shares of Elevance Health from $512.00 to $522.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 23rd. Cantor Fitzgerald restated an “overweight” rating and set a $485.00 price target on shares of Elevance Health in a report on Wednesday, April 23rd. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $478.00 price objective on shares of Elevance Health in a report on Wednesday, April 23rd. Four investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $510.38.

Elevance Health Trading Down 1.9 %

NYSE:ELV opened at $404.52 on Friday. The firm has a market cap of $91.40 billion, a price-to-earnings ratio of 15.80, a P/E/G ratio of 1.18 and a beta of 0.66. The company’s 50 day moving average is $424.13 and its 200-day moving average is $404.51. Elevance Health, Inc. has a 12 month low of $362.21 and a 12 month high of $567.26. The company has a quick ratio of 1.50, a current ratio of 1.45 and a debt-to-equity ratio of 0.71.

Elevance Health (NYSE:ELV) last announced its earnings results on Tuesday, April 22nd. The company reported $11.97 earnings per share for the quarter, beating the consensus estimate of $10.60 by $1.37. The firm had revenue of $48.77 billion during the quarter, compared to the consensus estimate of $46.26 billion. Elevance Health had a return on equity of 18.28% and a net margin of 3.38%. Equities analysts anticipate that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 25th. Shareholders of record on Tuesday, June 10th will be issued a $1.71 dividend. The ex-dividend date is Tuesday, June 10th. This represents a $6.84 annualized dividend and a yield of 1.69%. Elevance Health’s dividend payout ratio (DPR) is 26.69%.

Insiders Place Their Bets

In other news, CAO Ronald W. Penczek sold 443 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $415.13, for a total value of $183,902.59. Following the completion of the transaction, the chief accounting officer now directly owns 1,847 shares of the company’s stock, valued at approximately $766,745.11. This represents a 19.34 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Mark Kaye sold 4,588 shares of the company’s stock in a transaction on Thursday, April 24th. The shares were sold at an average price of $424.82, for a total value of $1,949,074.16. Following the completion of the sale, the chief financial officer now owns 18,977 shares in the company, valued at $8,061,809.14. This trade represents a 19.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 8,535 shares of company stock worth $3,521,612. 0.29% of the stock is currently owned by company insiders.

Elevance Health Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.